Skip to content

A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate in Lateral Epicondylitis (Tennis Elbow)

A Prospective, Multicentric, Open Label, Randomised, Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For The Treatment Of Lateral Epicondylitis (Tennis Elbow)

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01668862
Enrollment
20
Registered
2012-08-20
Start date
2012-03-31
Completion date
2012-11-30
Last updated
2012-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Epicondylitis (Tennis Elbow)

Brief summary

This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of human Platelet Lysate (HPL) in subjects with Lateral Epicondylitis (Tennis Elbow). The study is being conducted in 2 centers in India. The primary end points are Visual Analog Score (VAS) and Patient rated tennis elbow evaluation (PRTEE) score. The secondary endpoint is improvement in ultrasonography form randomization to End of study.

Interventions

Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space

DRUGCorticosteroid

Subjects will receive one injection of Corticosteroid in the lateral epicondyle space

Sponsors

Kasiak Research Pvt. Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Subjects with clinical diagnosis of tennis elbow within the last 3 months * Subjects both male and female, aged 18-60 years (both inclusive) * Subjects who are willing to give informed consent and adhere to the study protocol

Exclusion criteria

* Subjects aged less than 18 and more than 60 years * Subjects with autoimmune diseases * Subjects with immuno-compromised system * Subjects on Anti-coagulant therapy or blood thinning medicines like Aspirin * Subjects taking concomitant therapy that might interfere with the study results in investigators opinion or who had concomitant other injury of the tennis elbow tendons. * Subjects who have received treatment with corticosteroid injections within the last 6 months

Design outcomes

Primary

MeasureTime frame
Change in Visual Analog Score (VAS)Day 0, Month 1, Month 2, End of Study - Month 3

Secondary

MeasureTime frame
Change in Ultrasonography of the lateral epicondyle region from Baseline to End of study at Month 3Day 0, End of study - Month 3

Other

MeasureTime frame
Patient rated tennis elbow evaluation (PRTEE Score)Day 0, Month 1, Month 2, End of study-Month 3
The American Shoulder and Elbow Society scoreDya 0, Month 1, Month 2, End of study-Month 3

Countries

India

Contacts

Primary ContactKaushal Shah, Phd
kaushal.shah@kasiakresearch.com+91-22-41173472

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026